APOB and metabolic dysfunction-associated steatotic liver disease: If the decline of VLDL production does precede the impairment in global hepatic synthetic function, one might expect that apoB production can serve as a potential surrogate marker to replace the rather invasive liver biopsy for monitoring NAFLD disease progression.